Oculis Holding AG Ordinary shares - OCS STOCK NEWS

Oculis has announced the vesting of earnout shares and the removal of restrictions on these ordinary shares.

The notifications involve key managerial figures, including Anthony Rosenberg, Riad Sherif, Sylvia Cheung, and Pall Johanesson. Each notification details specific transactions related to these individuals.

The vesting of these shares signifies a notable event for the company and its stakeholders, potentially impacting stock performance due to changes in share availability and managerial ownership.

Oculis has announced a one-time equity incentive award issued to a director for his independent services as a consultant. The notification of this managerial transaction involves Arshad Khanani and was published in November 2024.

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care and sight preservation, has announced its participation in the Stifel 2024 Healthcare Conference. The event will take place on November 18-19, 2024, at the Lotte New York Palace Hotel. Sylvia Cheung, Chief Financial Officer, will participate in a fireside chat on November 18 at 3:35 pm ET. The presentation will be available via live webcast, and the company will conduct one-on-one meetings with investors during the conference. Access to the fireside chat will be provided through Oculis' website under the Investors & Media section.

Oculis Holding AG (Nasdaq: OCS) reported Q3 2024 financial results with cash position of $125.0 million, providing runway into 2H 2026. The company achieved significant enrollment progress in its DIAMOND Phase 3 trials, with ~70% enrolled in DIAMOND-1 and ~40% in DIAMOND-2. Research and development expenses increased to $15.0 million, up from $10.0 million in Q3 2023. The company reported a Q3 net loss of $23.3 million. Key upcoming milestones include OCS-05 Phase 2 ACUITY trial topline results expected in December 2024 and planned NDA submission readiness for OCS-01 in Q1 2025.

Oculis Holding AG (Nasdaq: OCS) announces accelerated patient enrollment for its Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME). The DIAMOND program has made substantial progress, with ~70% of patients enrolled in DIAMOND-1 and ~40% in DIAMOND-2. The company has also expanded its DIAMOND program committees with globally renowned retina experts.

The DIAMOND trials are evaluating the efficacy and safety of OCS-01 eye drops in DME patients. If approved, OCS-01 could potentially transform the treatment paradigm as the first topical eye drop to treat DME. Results from Stage 1 of the program showed significant improvements in visual acuity and clinically meaningful reduction in macular edema for patients treated with OCS-01.

Oculis Holding AG (Nasdaq: OCS) announces accelerated patient enrollment for both Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME). The DIAMOND-1 trial has enrolled ~70% of patients, while DIAMOND-2 has enrolled ~40%. The company has also expanded its DIAMOND program committees with globally renowned retina experts.

The DIAMOND program consists of two Phase 3, double-masked, randomized, multi-center trials evaluating the efficacy and safety of OCS-01 eye drops in DME patients. If approved, OCS-01 has the potential to be the first topical eye drop to treat DME, potentially transforming the treatment paradigm.

Dr. Arshad M. Khanani, DIAMOND Program Steering Committee Chairperson, highlighted promising results from Stage 1 of the DIAMOND Phase 3 program, showing significant improvements in visual acuity and clinically meaningful reduction in macular edema for patients treated with OCS-01.

Oculis Holding AG (Nasdaq: OCS) announced that updates on its DIAMOND Phase 3 program for OCS-01, an OPTIREACH® formulation of high concentration dexamethasone eye drop for diabetic macular edema (DME), will be presented at two upcoming events. Dr. David Eichenbaum will present at Innovate Retina, while Dr. Riad Sherif, Oculis' CEO, will present at Eyecelerator 2024.

Both presentations will highlight the robust results from Stage 1 of the DIAMOND program at Week 12 and present the design of Stage 2, which will assess efficacy and safety at Week 52. The ongoing DIAMOND-1 and DIAMOND-2 Phase 3 trials aim to enroll 350 patients each. Additionally, Dr. Sherif will discuss upcoming milestones, including topline results from the ACUITY Phase 2 trial with OCS-05 for acute optic neuritis, expected before the end of 2024.

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company focused on eye care, has appointed Daniel S. Char as Chief Legal Officer. Mr. Char brings over 35 years of global legal leadership experience in biotech and medical device companies. He will lead Oculis' legal, compliance, and corporate governance functions.

This appointment aligns with Oculis' strategic plan to advance its innovative pipeline, particularly OCS-01, the first topical eye drop in retina. Mr. Char's extensive expertise includes corporate governance, compliance, drug development and commercialization, financing, licensing, and M&A transactions.

Prior to joining Oculis, Mr. Char served as Chief Legal Officer at ImmunoGen and General Counsel at Evelo Biosciences. He has also held senior legal positions at Smith & Nephew, Targanta Therapeutics, and Biogen. Mr. Char holds a Juris Doctor from Harvard Law School and a Bachelor of Arts in Economics from Tufts University.

Oculis Holding AG (Nasdaq: OCS) and EURETINA have announced Dr. Andrea Govetto as the winner of the inaugural Ramin Tadayoni Award. This award, established in memory of Oculis' late Chief Scientific Officer, aims to support outstanding retina research. Dr. Govetto's winning project focuses on developing a computational model of fluid flow and retinal tissue deformation in macular edema.

The award, presented at the EURETINA congress in Barcelona, includes €30,000 for research support and an additional €5,000 for the awardee. It recognizes promising ophthalmologists in retina research, honoring Prof. Tadayoni's legacy. Dr. Govetto, a vitreoretinal surgeon at Oftalmico-Fatebenefratelli Hospital in Milan, was selected from over 50 competitive submissions.

Oculis CEO, Dr. Riad Sherif, expressed pride in supporting the award and advancing retinal disease research. EURETINA President, Dr. Anat Loewenstein, congratulated Dr. Govetto and highlighted the award's significance in furthering Prof. Tadayoni's contributions to the field.